Rocket Pharmaceuticals Warrant
RCKTW
15 hedge funds and large institutions have $426K invested in Rocket Pharmaceuticals Warrant in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
4.01% more ownership
Funds ownership: 0% → 4.01% (+4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$138K |
| 2 |
SCM
Sio Capital Management
New York
|
+$77.2K |
| 3 |
FBCM
Fort Baker Capital Management
Larkspur,
California
|
+$72.8K |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$70.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$69K |
Top Sellers
RCKTW Hedge Fund Activity: Q1 2023 in Review
15 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals Warrant (RCKTW) for Q1 2023, worth a combined $426K.
Buyers outnumbered sellers: 15 funds opened new RCKTW positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Walleye Capital, opening a new position worth an estimated $138K.
- 15 institutional investors held Rocket Pharmaceuticals Warrant (RCKTW) as of Q1 2023, up from 0 in Q4 2022.
- Funds reported $426K of Rocket Pharmaceuticals Warrant stock for Q1 2023.
- 15 funds opened new Rocket Pharmaceuticals Warrant positions in Q1 2023 and 0 closed out, a net change of +15 holders.
- The largest Rocket Pharmaceuticals Warrant buyer in Q1 2023 was Walleye Capital, an estimated $138K added.
Based on aggregated 13F filings for Q1 2023.